

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently amended) A method for preventing or ameliorating a symptom of ethanol intolerance in a subject with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity comprising orally administering to the subject about 0.1 mg to about 1.0 mg 4-methylpyrazole (4-MP) per kilogram of the subject's body mass.
2. (Original) The method of Claim 1, wherein 4-MP is administered in a free base form.
3. (Original) The method of Claim 1, wherein 4-MP is administered in a physiologically acceptable salt form.
4. (Original) The method of Claim 1, wherein 4-MP is orally administered before the subject consumes ethanol.
5. (Original) The method of Claim 4, wherein 4-MP is orally administered about one hour to about fifteen minutes before the subject consumes ethanol.
6. (Original) The method of Claim 1, wherein 4-MP is orally administered concurrently with the subject's consumption of ethanol or after the subject has consumed ethanol.
7. (Original) The method of Claim 1, wherein the percent reduction in the subject's ethanol elimination rate is no more than about 10% in comparison to the ethanol elimination rate of a subject not administered 4-MP.
8. (Currently amended) A method of preventing or reducing a symptom associated with acetaldehyde accumulation accompanying ethanol consumption in a subject with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity comprising administering an effective amount of 4-MP that reduces acetaldehyde accumulation by about 50% to about 60% as compared to a subject not administered 4-MP, wherein about 0.1 mg to about 1.0 mg 4-MP per kilogram of the subject's body mass is administered.

9. (Original) The method of Claim 8, wherein the subject with reduced or absent ALDH2 activity exhibits a percent reduction in ethanol elimination rate that is no more than about 10% in comparison to the ethanol elimination rate of a subject not administered 4-MP.

10. (Previously presented) A method of ameliorating a symptom of acetaldehyde accumulation accompanying ethanol consumption in a subject with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity comprising administering an amount of 4-MP or a physiologically acceptable salt of 4-MP effective to reduce or inhibit ethanol-oxidizing activity of alcohol dehydrogenase in the subject, wherein about 0.1 mg to about 1.0 mg 4-MP per kilogram of the subject's body mass is administered.

11. (Original) The method of Claim 8 or 10, wherein a symptom of acetaldehyde accumulation in the subject with reduced or absent ALDH2 activity is selected from the group consisting of flushing, elevated heart rate, palpitations, hypotension, nausea, dizziness, and headache.

12. (Original) The method of Claim 10 wherein an effective amount of a hydrochloride salt of 4-MP is administered.

13.-20. (Canceled).

21. (Previously presented) The method of claims 1, 8 or 10 wherein about 1.0 mg 4-MP per kilogram of the subject's body mass is administered.

22. (Previously presented) The method of claims 1, 8 or 10 wherein about 0.5 mg 4-MP per kilogram of the subject's body mass is administered.

23. (Canceled).